FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like EMA Proposes Single Guide for Clinical Evaluations of Bacterial Infection Treatments June 14, 2018 Aurobindo Facility in India Draws FDA Warning Letter India January 26, 2022 Lundbeck Reports Favorable Results in Chronic Migraine Study for Vyepti April 6, 2022